Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Pain ; 86(1-2): 113-8, 2000 May.
Artículo en Inglés | MEDLINE | ID: mdl-10779668

RESUMEN

The anti-nociceptive and locomotor effects of the nicotinic acetylcholine receptor (nAChR) agonists (+)-epibatidine and ABT-594 were compared in the rat. Acute thermal nociception was measured using the tail flick test. Mechanical hyperalgesia was measured as paw withdrawal threshold (PWT) in response to a mechanical stimulus in two animal models of persistent pain; (1) 24 h following subplantar injections of Freund's complete adjuvant (FCA) into the left hind paw or (2) 11-15 days following a partial ligation of the left sciatic nerve. Disruption of locomotor function was assessed using an accelerating rotarod device. In all tests, (+)-epibatidine was significantly more potent than ABT-594. Both (+)-epibatidine and ABT-594 dose-dependently increased tail flick latencies but only at doses that also disrupted performance in the rotarod test. On the other hand, (+)-epibatidine and ABT-594 dose-dependently reversed inflammatory and neuropathic hyperalgesia at significantly lower doses than that needed to disrupt performance in the rotarod test. In summary, ABT-594 is less potent than (+)-epibatidine in assays of acute and persistent pain and in the rotarod assay. However, ABT-594 displayed a clearer separation between its motor and anti-hyperalgesic effects. This shows that nicotinic agonists with improved selectivity between the nicotinic receptor subtypes could provide strong analgesic effects with a much improved therapeutic window.


Asunto(s)
Analgésicos no Narcóticos/farmacología , Azetidinas/farmacología , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Inflamación/complicaciones , Agonistas Nicotínicos/farmacología , Dolor/tratamiento farmacológico , Piridinas/farmacología , Receptores Nicotínicos/efectos de los fármacos , Neuropatía Ciática/complicaciones , Animales , Artritis Experimental/complicaciones , Relación Dosis-Respuesta a Droga , Adyuvante de Freund , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/psicología , Masculino , Dolor/etiología , Dimensión del Dolor/efectos de los fármacos , Equilibrio Postural/efectos de los fármacos , Ratas , Ratas Wistar
2.
Neuropharmacology ; 40(1): 1-9, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11077065

RESUMEN

The excitatory neurotransmitter, glutamate, is particularly important in the transmission of pain information in the nervous system through the activation of ionotropic and metabotropic glutamate receptors. A potent, subtype-selective antagonist of the metabotropic glutamate-5 (mGlu5) receptor, 2-methyl-6-(phenylethynyl)-pyridine (MPEP), has now been discovered that has effective anti-hyperalgesic effects in models of inflammatory pain. MPEP did not affect rotarod locomotor performance, or normal responses to noxious mechanical or thermal stimulation in naïve rats. However, in models of inflammatory pain, systemic administration of MPEP produced effective reversal of mechanical hyperalgesia without affecting inflammatory oedema. In contrast to the non-steroidal anti-inflammatory drugs, indomethacin and diclofenac, the maximal anti-hyperalgesic effects of orally administered MPEP were observed without acute erosion of the gastric mucosa. In contrast to its effects in models of inflammatory pain, MPEP did not produce significant reversal of mechanical hyperalgesia in a rat model of neuropathic pain.


Asunto(s)
Antagonistas de Aminoácidos Excitadores/uso terapéutico , Nociceptores/efectos de los fármacos , Dolor/tratamiento farmacológico , Receptores de Glutamato Metabotrópico/antagonistas & inhibidores , Animales , Antiinflamatorios no Esteroideos/efectos adversos , Enfermedad Crónica , Antagonistas de Aminoácidos Excitadores/efectos adversos , Hiperalgesia/tratamiento farmacológico , Masculino , Actividad Motora/efectos de los fármacos , Dolor/psicología , Dimensión del Dolor/efectos de los fármacos , Piridinas/farmacología , Ratas , Ratas Sprague-Dawley , Receptor del Glutamato Metabotropico 5 , Úlcera Gástrica/inducido químicamente , Úlcera Gástrica/patología
3.
Neuroscience ; 87(3): 527-32, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9758219

RESUMEN

Neuropathic pain is poorly managed by conventional analgesic therapy, such as non-steroidal anti-inflammatory drugs and opiates. The development of animal models of peripheral neural damage has aided in our understanding of the pathology and pharmacology of neuropathic pain. This report is the first clear demonstration using selective neurokinin-1 receptor antagonists of a potentially novel therapeutic approach to the treatment of neuropathic pain resulting from peripheral nerve damage in a guinea-pig model. The neurokinin-1 receptor antagonists, SDZ NKT 343 and LY 303,870 significantly reduced mechanical hyperalgesia following oral and intrathecal administration. (R,R)-SDZ NK T343, the enantiomer of SDZ NKT 343 did not show anti-hyperalgesic activity. RPR 100,893 showed significant anti-hyperalgesic activity only following intrathecal administration suggesting poor absorption or low level penetration of the blood-brain barrier. These results imply that neurokinin-1 receptor antagonists offer a new class of anti-hyperalgesic drugs with a largely central site of action in neuropathic pain.


Asunto(s)
Hiperalgesia/tratamiento farmacológico , Naftalenos/farmacología , Neuralgia/tratamiento farmacológico , Antagonistas del Receptor de Neuroquinina-1 , Prolina/análogos & derivados , Receptores de Neuroquinina-1/fisiología , Administración Oral , Animales , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Cobayas , Hiperalgesia/fisiopatología , Indoles/farmacología , Inyecciones Espinales , Isoindoles , Fibras Nerviosas/fisiología , Neuralgia/fisiopatología , Neuronas Aferentes/efectos de los fármacos , Neuronas Aferentes/fisiología , Neuronas Aferentes/ultraestructura , Piperidinas/farmacología , Prolina/farmacología , Médula Espinal/citología
4.
Prostaglandins Other Lipid Mediat ; 60(1-3): 15-26, 2000 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-10680772

RESUMEN

Phospholipases A2 (PLA2) and cyclooxygenases (COX) are important enzymes responsible for production of potent lipid mediators, including prostaglandins (PG) and thromboxane A2. We investigated coupling between PLA2 and COX isoforms by using transient transfection in COS-1 cells. Untransfected cells, incubated with or without phorbol ester + the Ca2+ ionophore ionomycin, generated trivial amounts of PGE2. In cells co-transfected with cytosolic PLA2 (cPLA2) and COX-1 or COX-2, phorbol ester + ionomycin markedly stimulated PGE2 production. There was no preferential coupling of cPLA2 to either of the COX isoforms. In contrast, group IIA secretory PLA2 (sPLA2) co-transfected with COX-1 or COX-2 did not lead to an increase in PGE2 production, despite high levels of sPLA2 enzymatic activity. Transfection of cPLA2 did not affect basal free arachidonic acid (AA) levels. Phorbol ester + ionomycin stimulated release of AA in cPLA2-transfected COS-1 cells, but not in untransfected cells, whereas sPLA2 transfection (without stimulation) led to high basal free AA. Thus, AA released by cPLA2 is accessible to both COX isoforms for metabolism to PG, whereas AA released by sPLA2 is not metabolized by COX.


Asunto(s)
Citosol/enzimología , Isoenzimas/metabolismo , Fosfolipasas A/metabolismo , Prostaglandina-Endoperóxido Sintasas/metabolismo , Animales , Células COS , Ciclooxigenasa 1 , Ciclooxigenasa 2 , Ionomicina/farmacología , Fosfolipasas A/genética , Fosfolipasas A2 , Plásmidos , Acetato de Tetradecanoilforbol/farmacología , Transfección
6.
Ann Rheum Dis ; 64 Suppl 4: iv70-6, 2005 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16239393

RESUMEN

Members of the tumour necrosis factor (TNF)/TNF-receptor (TNF-R) superfamily coordinate the immune response at multiple levels. For example, TNF, LTalpha, LTbeta and RANKL provide signals required for lymphoid neogenesis, CD27, OX-40, 4-1BB and CD30 deliver costimulatory signals to augment immune responses, while pro-apoptotic members such as TNF, CD95L and TRAIL may contribute to the termination of the response. Biological identity of individual family members has been revealed through studies of gain of function or gene deficient mutants. Most notable are the development of spontaneous inflammatory polyarthritis in human TNF-globin transgenic mice, the auto-inflammatory syndromes resulting from mutations in the 55-kDa TNF-R, and, in particular, the obligatory role for the RANKL/RANK axis in osteoclastogenesis and bone remodelling. A growing appreciation of the molecular basis of signalling pathways transduced by TNF-R has provided a framework for better understanding the biology of this expanding family. For while the rapid and robust activation of NF-kappaB and MAPK pathways is typical of acute TNF-R engagement, the molecular basis of sustained receptor signalling remains a mystery, in spite of its relevance to chronic inflammatory and immune responses. Focusing on T cells, this report describes some of the molecular footprints of sustained TNF-R engagement and illustrates how these may influence immune function. A common theme arising is that prolonged TNF stimulation alters signalling thresholds over time. The authors propose that one major outcome of long term exposure to TNF is a state of localised IL-2 deficiency at sites of inflammation. The implications of this deficiency are discussed.


Asunto(s)
Sistema Inmunológico/fisiopatología , Factor de Necrosis Tumoral alfa/fisiología , Animales , Artritis Reumatoide/inmunología , Homeostasis/inmunología , Humanos , Inflamación/inmunología , Interleucina-2/deficiencia , Ratones , Receptores del Factor de Necrosis Tumoral/fisiología , Transducción de Señal/inmunología , Linfocitos T/inmunología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores
7.
Histochem J ; 26(6): 504-18, 1994 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-7928404

RESUMEN

Previous studies of the normal human colorectum by lectin histochemistry have used a mixture of tissues, including those derived from colons harbouring neoplasia and inflammatory bowel diseases. In the current investigation, tissues from patients without either of these conditions have been examined with a wide panel of lectins, encompassing specificities directed against both N- and O-linked sequences, using an avidin peroxidase revealing system and evaluated with a semiquantitative scoring method. The results of binding of these lectins have been compared with those seen in the resection margins of (at least 5 cm away from) colorectal carcinomas. Consistent regional variations were noted between right- and left-sided colonic tissues, with more diverse glycan structures and a greater sialyl content in the distal colon. There was evidence of graduation of formation of oligosaccharide chains in developing crypts, possibly related to the maturation and expression of glycosyl transferases responsible for the incorporation of mannose residues of N-linked oligosaccharides and of N-acetylgalactosamine and N-acetylglucosamine. Comparison with previous reports has revealed some variations, possibly related to tissue fixation and processing and to lectin concentrations employed, which raises the question of standardization of methodologies in lectin histochemical investigations.


Asunto(s)
Colon/química , Glicoconjugados/análisis , Lectinas , Lectinas de Plantas , Recto/química , Neoplasias Colorrectales/química , Neoplasias Colorrectales/diagnóstico , Histocitoquímica/métodos , Humanos , Fitohemaglutininas , Proteínas Inactivadoras de Ribosomas , Fijación del Tejido
8.
Gen Pharmacol ; 26(6): 1349-54, 1995 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-7590130

RESUMEN

1. Siratiazem, an analogue of diltiazem designed to be resistant to N-demethylation, was compared with diltiazem for inhibition of Ca(2+)-induced contraction of depolarized coronary artery rings from the sheep. There was no significant difference in potency between siratiazem and diltiazem in the presence of normal physiological salt solution (IC25 for siratiazem 0.13 +/- 0.04 microM and for diltiazem 0.08 +/- 0.02 microM) or one mimicking some of the conditions that occur during myocardial ischaemia (hypoxia, acidosis, reduced glucose and addition of lactate). 2. K(+)-stimulated 45Ca2+ uptake in coronary artery rings was also inhibited by siratiazem and diltiazem with similar potencies. 3. It is concluded that siratiazem inhibits Ca2+ entry in coronary vascular smooth muscle equipotently with diltiazem and that this effect is not modified by some of the changes that occur during myocardial ischaemia.


Asunto(s)
Antiarrítmicos/farmacología , Calcio/metabolismo , Vasos Coronarios/efectos de los fármacos , Diltiazem/análogos & derivados , Diltiazem/farmacología , Músculo Liso Vascular/efectos de los fármacos , Animales , Calcio/farmacología , Relación Dosis-Respuesta a Droga , Contracción Muscular , Cloruro de Potasio/farmacología , Ovinos
9.
J Auton Pharmacol ; 15(2): 107-13, 1995 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7615573

RESUMEN

1. The aim of this study was to compare the abilities of diltiazem and siratiazem to inhibit concentration-response curves for contractile responses to calcium in arterial and intestinal smooth muscle and cardiac muscle. 2. Diltiazem and siratiazem inhibited, in a concentration-dependent manner, the maximum contraction produced by cumulative addition of calcium chloride to rabbit mesenteric artery, ileum and paced atria in vitro. The order of potency, as indicated by the IC25 values (with 95% confidence intervals) for siratiazem was ileum, 0.33 microM (0-0.63) > mesenteric artery, 0.75 microM (0.32-1.01) and for diltiazem was ileum 0.1 microM (0.007-0.14) = mesenteric artery 0.13 microM (0-0.22). 3. In rabbit atria, the IC25 was of the order of 10 microM for both siratiazem and diltiazem. 4. Both drugs also inhibited calcium concentration-response curves in sheep cerebral arteries and in this tissue the IC25 values were 1.18 (0.37-1.63) and 0.89 (0-1.36) microM for siratiazem and diltiazem, respectively. 5. It is concluded that siratiazem, like diltiazem, blocks entry of calcium via voltage-operated channels with a similar potency to diltiazem on rabbit ileum and cardiac muscle and sheep cerebral arteries but is less potent on rabbit mesenteric arteries.


Asunto(s)
Antiarrítmicos/farmacología , Bloqueadores de los Canales de Calcio/farmacología , Diltiazem/análogos & derivados , Músculo Liso Vascular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Contracción Miocárdica/efectos de los fármacos , Animales , Calcio/farmacología , Arterias Cerebrales/efectos de los fármacos , Diltiazem/farmacología , Íleon/efectos de los fármacos , Técnicas In Vitro , Masculino , Arterias Mesentéricas/efectos de los fármacos , Contracción Muscular/efectos de los fármacos , Conejos , Ovinos
10.
J Immunol ; 159(7): 3584-94, 1997 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-9317158

RESUMEN

In rat membranous nephropathy, C5b-9 induces glomerular epithelial cell (GEC) injury and proteinuria, which is partially mediated by eicosanoids. In cultured rat GEC, sublytic C5b-9 injures plasma membranes and releases arachidonic acid (AA) and eicosanoids, due to activation of phospholipase A2 (PLA2). To address mechanisms of PLA2 activation, GEC were stably transfected with cDNAs of wild-type cytosolic PLA2 (cPLA2-wt), or group II secretory PLA2, producing overexpression of PLA2 activity. Sublytic C5b-9 markedly increased free [3H]AA in cPLA2-wt-transfected GEC, but only trivial increases were evident in secretory PLA2-transfected, or neo (control) GEC. In cPLA2-wt-transfected GEC, reduction of extracellular free Ca2+ or down-regulation of protein kinase C inhibited [3H]AA release. To further address the regulation of cPLA2, we stably expressed a mutant cPLA2 in which the Ca2+-dependent lipid binding domain was deleted (deltaCaLB). In GEC that express cPLA2-deltaCaLB, the C5b-9-induced increase in free [3H]AA was comparable with neo, despite expression of cPLA2-deltaCaLB at levels similar to cPLA2-wt. We then stably expressed another cPLA2 mutant (cPLA2-srcmyr) in which the CaLB domain was replaced by the N-terminal myristoylation domain of c-Src. cPLA2-srcmyr is permanently membrane associated. At low extracellular free Ca2+, C5b-9 increased free [3H]AA significantly in GEC that express cPLA2-srcmyr, while in neo GEC, the change was negligible. Thus, C5b-9 activates the cPLA2 isoform. Activation is dependent on the CaLB domain, and is mediated by phosphorylation, Ca2+ influx, and membrane association.


Asunto(s)
Complejo de Ataque a Membrana del Sistema Complemento/fisiología , Glomérulos Renales/enzimología , Glomérulos Renales/inmunología , Fosfolipasas A/metabolismo , Animales , Ácido Araquidónico/metabolismo , Células COS , Calcio/fisiología , Células Cultivadas , Citosol/enzimología , Activación Enzimática/inmunología , Células Epiteliales , Epitelio/enzimología , Epitelio/inmunología , Glomérulos Renales/citología , Metabolismo de los Lípidos , Mutagénesis Sitio-Dirigida , Fosfolipasas A/biosíntesis , Fosfolipasas A/genética , Fosfolipasas A2 , Proteína Quinasa C/fisiología , Estructura Terciaria de Proteína , Ratas
11.
Circulation ; 95(1): 125-32, 1997 Jan 07.
Artículo en Inglés | MEDLINE | ID: mdl-8994427

RESUMEN

BACKGROUND: The three major classes of antianginal drug all inhibit platelet aggregation at high concentrations in vitro, but detecting clinically relevant effects has proved to be more difficult. We used whole-blood flow cytometry, a sensitive method that allows direct measurement of activation antigens on the surface of individual platelets in whole unfixed blood, to evaluate the effect of representative antianginal drugs on platelet function in vivo in healthy volunteers. METHODS AND RESULTS: The effects of glyceryl trinitrate (GTN), amlodipine, and atenolol were studied in nine normal volunteers. Fibrinogen binding to activated GP IIb/IIIa and expression of P-selectin, GP Ib, and GP IIb/IIIa on the platelet surface were measured. In addition, fibrinogen binding and P-selectin expression were measured in response to ex vivo stimulation with the agonists ADP and thrombin. The three drugs had very different effects on platelets. GTN inhibited platelet fibrinogen binding and expression of P-selectin at rest and in response to agonist stimulation, whereas amlodipine enhanced P-selectin expression and atenolol increased fibrinogen binding in response to agonists. Atenolol did not block the stimulatory effects of epinephrine on ADP-induced platelet activation. GTN neutralized the proactivatory effects of amlodipine, whereas the effects of atenolol and amlodipine were not additive. CONCLUSIONS: The three main classes of antianginal medication have different and possible clinically relevant effects on platelet behavior in vivo, nitrates causing inhibition of aggregation (fibrinogen binding) and degranulation (P-selectin expression), calcium antagonists enhancing degranulation, and beta-blockers enhancing aggregation.


Asunto(s)
Antagonistas Adrenérgicos beta/farmacología , Bloqueadores de los Canales de Calcio/farmacología , Nitroglicerina/farmacología , Activación Plaquetaria/efectos de los fármacos , Antagonistas Adrenérgicos beta/uso terapéutico , Adulto , Amlodipino/farmacología , Amlodipino/uso terapéutico , Angina Inestable/tratamiento farmacológico , Atenolol/farmacología , Atenolol/uso terapéutico , Plaquetas/efectos de los fármacos , Bloqueadores de los Canales de Calcio/uso terapéutico , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Citometría de Flujo , Humanos , Masculino , Nitroglicerina/uso terapéutico
12.
J Immunol ; 166(9): 5495-507, 2001 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-11313388

RESUMEN

A role for TNF-alpha in the pathogenesis of chronic inflammatory disease is now firmly established. Paradoxically, TNF also has potent immunomodulatory effects on CD4(+) T lymphocytes, because Ag-specific proliferative and cytokine responses are suppressed following prolonged exposure to TNF. We explored whether TNF attenuated T cell activation by uncoupling proximal TCR signal transduction pathways using a mouse T cell hybridoma model. Chronic TNF exposure induced profound, but reversible, T cell hyporesponsiveness, with TNF-treated T cells requiring TCR engagement with higher peptide concentrations for longer periods of time for commitment to IL-2 production. Subsequent experiments revealed that chronic TNF exposure led to a reversible loss of TCRzeta chain expression, in part through a reduction in gene transcription. Down-regulation of TCRzeta expression impaired TCR/CD3 assembly and expression at the cell surface and uncoupled membrane-proximal tyrosine phosphorylation events, including phosphorylation of the TCRzeta chain itself, CD3epsilon, ZAP-70 protein tyrosine kinase, and linker for activation of T cells (LAT). Intracellular Ca(2+) mobilization was also suppressed in TNF-treated T cells. We propose that TNF may contribute to T cell hyporesponsiveness in chronic inflammatory and infectious diseases by mechanisms that include down-regulation of TCRzeta expression. We speculate that by uncoupling proximal TCR signals TNF could also interrupt mechanisms of peripheral tolerance that are dependent upon intact TCR signal transduction pathways.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales , Regulación hacia Abajo/inmunología , Proteínas de la Membrana/antagonistas & inhibidores , Proteínas de la Membrana/biosíntesis , Complejo Receptor-CD3 del Antígeno de Linfocito T/antagonistas & inhibidores , Complejo Receptor-CD3 del Antígeno de Linfocito T/biosíntesis , Receptores de Antígenos de Linfocitos T/antagonistas & inhibidores , Receptores de Antígenos de Linfocitos T/biosíntesis , Factor de Necrosis Tumoral alfa/farmacología , Acetilcisteína/farmacología , Animales , Señalización del Calcio/inmunología , Proteínas Portadoras/metabolismo , Línea Celular Transformada , Membrana Celular/genética , Membrana Celular/inmunología , Membrana Celular/metabolismo , Supresión Clonal , Relación Dosis-Respuesta Inmunológica , Regulación hacia Abajo/efectos de los fármacos , Humanos , Hibridomas , Tolerancia Inmunológica/efectos de los fármacos , Interleucina-2/antagonistas & inhibidores , Interleucina-2/biosíntesis , Activación de Linfocitos/efectos de los fármacos , Activación de Linfocitos/genética , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Ratones , Ratones Transgénicos , Fosfoproteínas/metabolismo , Fosforilación , Proteínas Tirosina Quinasas/metabolismo , Complejo Receptor-CD3 del Antígeno de Linfocito T/genética , Complejo Receptor-CD3 del Antígeno de Linfocito T/metabolismo , Receptores de Antígenos de Linfocitos T/genética , Receptores de Antígenos de Linfocitos T/metabolismo , Proteínas Recombinantes de Fusión/fisiología , Transducción de Señal/genética , Transducción de Señal/inmunología , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Linfocitos T/metabolismo , Factores de Tiempo , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Proteína Tirosina Quinasa ZAP-70
13.
Arthritis Rheum ; 37(11): 1689-97, 1994 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-7526872

RESUMEN

OBJECTIVE: To examine intercellular adhesion molecule 1 (ICAM-1) and lymphocyte function-associated antigen 3 (LFA-3) in cultures of normal and systemic sclerosis (SSc) dermal fibroblasts. METHODS: The surface and soluble forms of ICAM-1 and LFA-3 were measured by flow cytometry and capture enzyme-linked immunosorbent assay, respectively. RESULTS: Surface ICAM-1 was significantly higher on SSc fibroblasts compared with normal controls. Beta-estradiol did not directly enhance ICAM-1 or LFA-3 expression in either normal or SSc cells, but significantly augmented the cytokine-induced increase in ICAM-1. Soluble ICAM-1 (sICAM-1) and sLFA-3 were detected in fibroblast cultures. While no difference was found in the level of sLFA-3, the shedding of sICAM-1 was significantly increased (P < 0.001) in cells from SSc patients. CONCLUSION: SSc fibroblasts express intrinsically elevated levels of surface ICAM-1 and release higher levels of sICAM-1 in vitro. Increased expression of ICAM-1 by interferon-gamma and tumor necrosis factor alpha alone, and the further induction in combination with beta-estradiol may underlie an aspect of fibroblast dysfunction in SSc and the female predisposition to the disease.


Asunto(s)
Antígenos CD/metabolismo , Estradiol/farmacología , Molécula 1 de Adhesión Intercelular/metabolismo , Interferón gamma/farmacología , Glicoproteínas de Membrana/metabolismo , Esclerodermia Sistémica/inmunología , Factor de Necrosis Tumoral alfa/farmacología , Antígenos CD58 , Células Cultivadas , Ensayo de Inmunoadsorción Enzimática , Fibroblastos/efectos de los fármacos , Fibroblastos/inmunología , Citometría de Flujo , Humanos , Esclerodermia Sistémica/patología , Solubilidad
14.
Eur Heart J ; 20(10): 742-7, 1999 May.
Artículo en Inglés | MEDLINE | ID: mdl-10329065

RESUMEN

AIMS: The GPIIb-IIIa complex on the platelet membrane plays an important part in thrombosis as it is the receptor for fibrinogen. The gene for platelet membrane glyco-protein IIIa has multiple alleles one of which, the GPIIIa-Proline33 (HPA-1b, PlA2, Zwb) allele has been reported in some, but not all studies, to be associated with an increased risk of myocardial infarction. We investigated whether the presence of the Pro33 form of GPIIIa on the platelet membrane is associated with increased fibrinogen binding. METHODS AND RESULTS: Blood samples from 70 patients (54 male) with stable angina of whom 22 (18 male) had a history of previous myocardial infarction, were analysed for the GPIIIa-Leu-Pro33 polymorphism at the genomic level, and for whole blood flow cytometric measurement of platelet fibrinogen binding. The GPIIIa-Pro33 form was present in 20 (28.6%) patients (1 homozygous) representing an allele frequency of 0.85 and 0.15 (GPIIIa-Leu33:Pro33). The incidence of myocardial infarction was higher (40.0%) in patients positive for GPIIIa-Pro33 than in those without (32.0%) but this was not significant (P=0.58). Fibrinogen binding to ADP-stimulated platelets was significantly higher in the GPIIIa-Pro33 positive group at all ADP concentrations (<0.0001; two way ANOVA). There was no association between fibrinogen binding and the level of expression of the GPIIb-IIIa complex, platelet volume or platelet count. Fibrinogen binding in response to thrombin stimulation was not different between the groups (P>0.05). CONCLUSIONS: The increased tendency of platelets from patients with the Pro33 form of GPIIIa may predispose patients with this allele to a higher risk of acute thrombotic events, and argues for selective use of therapeutic agents that inhibit ADP-mediated platelet activation in occlusive vascular disease states.


Asunto(s)
Angina de Pecho/sangre , Plaquetas/metabolismo , Fibrinógeno/metabolismo , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/genética , Anciano , Alelos , ADN/análisis , Femenino , Citometría de Flujo , Humanos , Masculino , Persona de Mediana Edad , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/metabolismo , Polimorfismo Genético , Prolina/genética , Unión Proteica
15.
Arterioscler Thromb Vasc Biol ; 17(10): 2044-53, 1997 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9351370

RESUMEN

Platelet activation state and responsiveness to physiological agonists were measured in 65 patients with documented coronary artery disease (54 male and 11 female; mean age, 58 years). Twelve patients (mean age, 52 years), selected at random from the male cohort, were compared with 12 age-matched male control subjects (mean age, 52 years) and with 10 normal, young male subjects (mean age, 25 years). Whole-blood flow cytometry was used to measure platelet activation status ex vivo and platelet responsiveness to physiological agonists in vitro. Peripheral blood samples were analyzed for bound fibrinogen and expression of P-selectin, GPIb, and GPIIb-IIIa at rest and in response to ADP (0.1 to 10 mumol/L) and thrombin (0.02 to 0.32 mu/mL). No significant differences were seen in the basal levels of fibrinogen binding between any of the groups, but P-selectin expression was significantly lower in patients compared with age-matched control subjects (P = .0005). When stimulated with agonists, patients' platelets had significantly decreased fibrinogen binding (P < .03) but no difference in P-selectin expression compared with the age-matched group. Both agonist-induced fibrinogen binding and P-selectin expression were, however, higher in the young subjects compared with either the older control group or the patients (P < .05). GPIb and GPIIb-IIIa expression were lowest in the patients with angina and highest in the young control subjects, with levels in the age-matched control subjects falling between these values. Data from the total patient cohort (n = 65) were identical to those in the smaller cohort (n = 12). In conclusion, atherosclerosis impairs platelet aggregatory responses (fibrinogen binding) over and above the decreased response seen with age. Platelet degranulation (P-selectin expression) is also impaired in patients with coronary artery disease, but only in comparison with younger subjects, not age-matched controls.


Asunto(s)
Plaquetas/fisiología , Enfermedad Coronaria/sangre , Adulto , Factores de Edad , Anciano , Femenino , Fibrinógeno/análisis , Citometría de Flujo , Humanos , Masculino , Persona de Mediana Edad , Selectina-P/análisis , Activación Plaquetaria , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/análisis , Fumar/sangre
16.
Eur Heart J ; 19(8): 1239-48, 1998 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9740346

RESUMEN

AIMS: Platelet activation may be a determinant of thrombotic and restenotic complications following intracoronary stenting. In order to measure the effect of stenting on platelet activation antigen expression we used whole blood flow cytometry in 18 patients undergoing Palmaz-Schatz stenting (treated with full anticoagulation) and compared these with a group of 18 patients undergoing elective angioplasty. The effects of low molecular weight heparin and unfractionated heparin on platelet behaviour were also studied, both in vitro and in vivo to determine the contribution of prolonged heparin therapy to platelet activation following stenting. METHODS AND RESULTS: Fibrinogen binding to activated GPIIb-IIIa, and surface expression of P-selectin, GPIb and GPIIb-IIIa antigens were measured in unstimulated peripheral blood samples (rest) and on stimulation with adenosine diphosphate (0.1-10 micromol x 1(-1)) and thrombin (0.02-0.16 U x ml(-1)). No changes were seen in resting samples following angioplasty or stenting. Agonist responsiveness was unaltered after angioplasty, but in stented patients antigen expression in response to thrombin was significantly reduced (P< or =0.04), whilst the adenosine diphosphate response was significantly increased (P=0.01). Similar effects were observed in patients with unstable angina treated with either low molecular weight heparin or unfractionated heparin in vivo. In vitro, both unfractionated and low molecular weight heparin inhibited thrombin-induced platelet activation, but stimulation of adenosine diphosphate responses was more marked with unfractionated than low molecular weight heparin. CONCLUSIONS: There was a significant increase in platelet responsiveness to adenosine diphosphate following intracoronary stenting in patients treated with conventional anticoagulants. This was probably a consequence of treatment with heparin. Activation of platelets by heparin may explain the increased rate of stent thrombosis in patients treated with anticoagulant therapy. Low molecular weight heparins stimulate platelets less than unfractionated heparin.


Asunto(s)
Angina de Pecho/terapia , Anticoagulantes/efectos adversos , Heparina/efectos adversos , Activación Plaquetaria/efectos de los fármacos , Stents , Trombosis/inducido químicamente , Adenosina Difosfato/farmacología , Anciano , Angina de Pecho/fisiopatología , Femenino , Citometría de Flujo , Heparina de Bajo-Peso-Molecular/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Recuento de Plaquetas , Warfarina/farmacología
17.
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA